Cutera Introduces Novel Laser Wavelength for Cosmetic Dermatology

Cutera Enters Emerging Segment of Anti-Aging Market for Pronounced Clinical

Outcomes With Moderate Downtime

    BRISBANE, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Cutera, Inc.(R)
 ( CUTR), a leading provider of laser and light-based aesthetic
 systems for practitioners worldwide, today announced it will preview a new
 laser technology at the 65th annual meeting of the American Academy of
 Dermatology (AAD), February 2-6, 2007. The proprietary YSGG technology
 generates a 2790 nm wavelength, which has specialized optical
 characteristics for minimally-invasive aesthetic procedures. This
 represents the first application of this wavelength in cosmetic
 dermatology.
     "A growing number of patients and practitioners are interested in more
 pronounced improvement with moderate downtime in the treatment of fine
 lines, wrinkles and skin texture," said Kevin Connors, Cutera's CEO. "Our
 YSGG technology will allow us to participate in this emerging segment
 currently estimated at approximately $150 million and projected to be
 growing in excess of 30% per year."
     The YSGG technology removes a portion of the epidermis with a
 controlled amount of thermal effect. Mr. Connors continued, "We expect
 collagen remodeling without the wound-healing trauma and significant
 discomfort associated with traditional ablative procedures. The thermal
 effect also creates a natural protective dressing on the skin to ensure
 moderate downtime."
     The new YSGG technology complements Cutera's non-ablative, no-downtime
 aesthetic procedures. It will be available on Cutera's multi-application
 Xeo platform, as a standalone unit, and as an upgrade to all existing
 customers. Cutera filed a regulatory submission to the FDA in December 2006
 and will begin formal marketing efforts once clearance has been granted by
 the Agency.
     About Cutera, Inc.
     Brisbane, Calif.-based Cutera is a leading provider of laser and other
 light-based aesthetic systems to the professional aesthetic market. Since
 1998, Cutera has been developing innovative, easy-to-use products that
 enable dermatologists, plastic surgeons, gynecologists, primary care
 physicians and other qualified practitioners to offer safe and effective
 aesthetic treatments to their patients. For more information, call
 1-888-4CUTERA or visit www.cutera.com.
     This press release contains forward-looking statements within the
 meaning of the U.S. Private Securities Litigation Reform Act of 1995.
 Specifically, statements concerning the anticipated success of obtaining
 regulatory clearances, compiling effective clinical studies and making,
 marketing and selling new products are forward-looking statements within
 the meaning of the Safe Harbor. Forward-Looking statements are based on
 management's current, preliminary expectations and are subject to risks and
 uncertainties, which may cause Cutera's actual results to differ materially
 from the statements contained herein. Further information on potential risk
 factors that could affect Cutera's business and its financial results are
 detailed in its most recent 10-K and 10-Q as filed with the Securities and
 Exchange Commission. Undue reliance should not be placed on forward-looking
 statements which speak only as of the date they are made. Cutera undertakes
 no obligation to update publicly any forward-looking statements to reflect
 new information, events or circumstances after the date they were made, or
 to reflect the occurrence of unanticipated events.
 
 

SOURCE Cutera, Inc.